MDS, Inc. is divesting its Phase II-IV operations to INC Research for $50 million. MDS plans to focus on early stage discovery through Phase IIa CRO services. “We are taking action to enhance shareholder value by focusing our business portfolio on areas where we believe we can expand market leadership,” said Stephen P. DeFalco, president and chief executive officer, MDS Inc. “While our investments in MDS Pharma Services’ Late Stage have significantly strengthened the b...